BIOLOGICAL ACTIVITIES OF CANNABINOIDS

该提案包含几个独立但相关的目标， 来自我们以前和正在进行的机制研究， 大麻素的作用。 中心假设是THC和 其他大麻素对脂质代谢产生深远的影响， 特别是花生四烯酸的代谢， 在体外和体内， 类花生酸，如PGE 2。 在这个方案中，我们已经表明， 一些大麻素可以作为激动剂，另一些可以作为 对手。 目前的建议将直接解决可能的问题， 大麻素在模型中的激动剂-拮抗剂相互作用， 小鼠的僵硬反应。 四氢大麻酚及其 代表激动剂-拮抗剂对的酸性代谢物将 测量并与类二十烷酸的组织水平和 生物学终点，如僵住、镇痛和抗水肿 方面的影响. 建立这种互动关系将有助于 解释了THC的一些鲜为人知的影响。 另一 这些发现的后果将是一些穷人 了解THC的影响。 这些发现的另一个结果是 将是一个基础，一个更合理的方法， 开发大麻素的治疗用途。 最后，我们将探索大麻素的可能性，通过 由于它们的膜改变性质，可以用于 治疗逆转录病毒源疾病的新方法， 艾滋病 将进行实验，以确定可耐受的剂量是否 非精神活性大麻素可以显著抑制细胞 膜在体内。 这种膜的变化被认为是 降低逆转录病毒的感染性， 疾病的影响。

This proposal contains several independent but related goals which were derived from our previous and ongoing studies on the mechanism of action of cannabinoids. The central hypothesis is that THC and other cannabinoids exert profound effects on lipid metabolism, in particular, the metabolism of arachidonic acid which results in significant change both in vitro and in vivo in the production of eicosanoids such as PGE2. In this scheme we have shown that while some cannabinoids can behave as agonists, others can act as antagonists. The present proposal will directly address the question of possible agonist-antagonist interactions of cannabinoids in models such as the cataleptic response in mice. Relative levels of THC and its acid metabolites, which represent an agonist-antagonist pair, will be measured and compared with tissue levels of eicosanoids and with biological endpoints such as catalepsy, analgesia and anti-edema effects. The establishment of such an interaction would help explain some of the poorly understood effects of THC. A further consequence of these findings would be some of the poorly understood effects of THC. A further consequence of these findings would be a basis for a more rational approach toward the development of therapeutic uses for cannabinoids. Finally, we will explore the possibility that cannabinoids, by virtue of their membrane altering properties, could be used in a new approach to the treatment of diseases of retroviral origin such as AIDs. Experiments will be done to see whether tolerable doses of non-psychoactive cannabinoids can significantly fluidize cell membranes in vivo. Such changes in membranes are believed to decrease the infectivity of retroviruses resulting in a moderation of the effects of the disease.